HOYA/PENTAX Medical Issues Statement Regarding U.S. Department of Justice Settlement

PENTAX Medical

PR83593

 

MONTVALE, N.J. and TOKYO, April 8, 2020 /PRNewswire=KYODO JBN/ --

 

HOYA Corporation and a subsidiary through PENTAX Medical division, Pentax of

America, Inc. (collectively, "PENTAX" or "the Company"), today finalized a

Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice (DOJ)

on issues related to the timely filing of Medical Device Reports (MDRs) for

PENTAX Medical's duodenoscopes and providing updated Instructions for Use

(IFUs) for several PENTAX Medical products. PENTAX first disclosed the DOJ

investigation in June 2015.

 

Logo - https://mma.prnewswire.com/media/1076915/Pentax_Logo.jpg

 

In the DPA, PENTAX acknowledged that it did not timely submit two required MDRs

to the U.S. Food and Drug Administration (FDA) for events in the US between

July 2013 and December 2014. In addition, PENTAX acknowledged that it failed to

send FDA approved IFUs for four types of endoscopes from April 2014 until

September 2015. PENTAX agreed to: pay a fine and forfeiture totaling $43

million; undertake new steps to enhance its compliance policies and procedures;

and regularly make certain certifications that PENTAX is meeting the

requirements of the DPA.

 

"PENTAX deeply regrets that it did not timely file the MDRs identified in the

DPA, as well as the failure to send the approved IFUs to customers. We accept

full responsibility for these failures," said David Woods, President of Pentax

of America, Inc.

 

The DPA does not allege any direct harm to patients as a result of the

disclosure failures or failure to send IFUs, and PENTAX acknowledged that it

failed to comply with the federal reporting requirements. The DPA does not

impact the availability of PENTAX Medical products and services worldwide.

 

"PENTAX Medical is committed to the highest standards of ethical behavior and

we are confident we can fulfill each of the obligations under this DPA to the

fullest extent necessary," said Gerry Bottero, Global President, PENTAX

Medical.

 

The full text of the DPA will be available on the PENTAX Medical website

(https://www.pentaxmedical.com/pentax/en/99/1/Compliance-and-Ethics ).

 

At PENTAX Medical, we have an unwavering commitment to our customers and their

patients to provide safe, high-quality products and services that offer true

value. To that end, we develop products and services that enable our customers

to improve clinical outcomes, reduce the cost of healthcare, and enhance the

experience they deliver to patients. This approach is demonstrated in how we

develop clinically relevant endoscopy products, advance cleaning procedures,

continuously improve our internal procedures, and empower our customers through

expert training and education programs. While we always strive to deliver on

our promises, how we achieve those results is equally as important.

 

About PENTAX Medical

PENTAX Medical is a division of HOYA Group. The company's mission is to improve

the standard of patient care and quality of healthcare delivery by providing

the best endoscopic products and services with a focus on QUALITY, CLINICALLY

RELEVANT INNOVATION, and SIMPLICITY.

Through providing endoscopic imaging devices and solutions to the global

medical community and with its headquartered in Japan, PENTAX Medical has a

worldwide focus and a strong presence with R&D, regional sales, service, and

in-country facilities in multiple regions around the globe.

PENTAX Medical's Triple Aim program strives to deliver on the commitment to

support its customers and their healthcare organization's wider objectives

through a transparent partnership and by providing the highest quality

solutions to help them reach their goals. Enabling customers to improve patient

outcomes by offering evidenced based solutions across the continuum of care,

dedicated to their needs. From screening through to therapy with full

scalabilities. Ensuring values by supporting the customers to improve their

efficiency and minimize their healthcare costs. Enriching patient and

provider's experience by empowering every member of the care team to achieve

optimal outcomes through products, education and support. For more information,

please visit: www.pentaxmedical.com. For more information, please visit

https://www.pentaxmedical.com.

 

About HOYA

Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and

med-tech company and a leading supplier of innovative high-tech and medical

products. HOYA's divisions and business units research and develop products

utilized in the healthcare and information technology fields.

In the healthcare field, we provide medical device products such as eyeglasses,

medical endoscopes, contact and intraocular lenses, orthopedic implants,

surgical/therapeutic devices and medical device reprocessing and disinfection

solutions. In the information technology field, we provide products such as

optical lenses, photomasks and blanks used in the manufacturing process for

semiconductor and LCD/OLED devices, text to speech, human resources and other

software solutions and critical components for the mass memory and cloud

storage industries. With over 150 offices and subsidiaries worldwide, HOYA

currently employs a multinational workforce of 37,000 people. For more

information, please visit http://www.hoya.com

 

Mariano Franco

1 (905) 580-7725

mariano.franco@pentaxmedical.com

 

SOURCE PENTAX Medical

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中